The day-long event saw senior executives from organizations including Astra Zeneca, the National Institutes of Health, the Lilly Research Laboratories, the Myelin Repair Foundation and the Clinical Data Interchange Standards Consortium (CDISC) discuss issues including:
- Diminishing returns on R&D investment as a result of increasing costs, long development times, changing global markets, heightened pressures on reimbursement from payors and low success rates of clinical approval
- An increasingly risk-averse regulatory environment governing the pharmaceutical sector globally
- Suboptimal collaboration among the private sector, academe and government to fully leverage innovations in translational science, novel development approaches and information sharing.
The solutions included:
- Using alternative models for research and development that entail innovative translational approaches to enable earlier proof-of-concept experiments in humans that improve the probability of success and R&D investment decisions
- Investment in emerging markets to leverage global talent and capacity
- Increasing innovation and capacity through strategic collaborations and partnerships among academe, government, pharmaceutical companies and service providers
- Re-defining a “pre-competitive space” in which stakeholders share collective learning and best practices and conduct coordinated research
- Leveraging recent innovations in information management technologies to integrate disparate and massive pre-clinical and clinical data sets to derive, share and apply iterative learning to decision-making
- The need to focus on comprehensive education and career development to train the next generation of drug discovery scientists.
The Advisory Board was brought together on Tuesday March 8 by GDS International to develop a programme for its industry-wide NG Pharmaceutical Summit in Arizona in May 2011.
The full list of Advisory Board attendees is below.
John C. Bloom VMD, Ph.D., President, Bloom Consulting Services
Michael J. Gresser Ph.D., Chief Scientific Officer, Myelin Repair Foundation
Rebecca D. Kush Ph.D., President and CEO, Clinical Data Interchange Standard Consortium (CDISC)
Kalpana M. Merchant Ph.D., Chief Scientific Officer Translational Science, Lilly Research Laboratories
Rajesh Ranganathan Ph.D., Senior Advisor to the Director, NIH
Keith Russell Ph.D., Global R&D Design & Innovation Continuous Improvement Leader, Astra Zeneca Pharmaceuticals
1. The Advisory Board convened to identify key issues for the GDS NG Pharmaceutical Summit in Scottsdale, Arizona in May 2011. For more information visit: http://www.ngpsummit.com/
Media contacts
Samia Yakub, Bell Pottinger Business & Brand syakub@bell-pottinger.co.uk, +44 77 6823 7632 or +44 7854 248 987
Adam Powell, Bell Pottinger Business & Brand apowell@bell-pottinger.co.uk, +44 20 7861 2514
